Odyssey Therapeutics, Inc.
ODTX
Rank in Stocks
#9047
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused... Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
Share Price
$19.15
Last synced: 2026-11-09
Market Cap
$920.32M
Change (1 day)
-0.42%
Change (1 year)
-
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Odyssey Therapeutics, Inc. (ODTX)
Category
Healthcare
EPS for Odyssey Therapeutics, Inc. (ODTX)
EPS as of September 2026 TTM: $-3.65
According to Odyssey Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-3.65. At the end of 2026 the company had an EPS of 0, equal to its 2026 EPS of 0.
EPS history for Odyssey Therapeutics, Inc. from 2025 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-3.65 | -32.28% |
| 2025 | $-5.39 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -529.04% |
US
|
|
| $-7.07 | 93.70% |
US
|
|
| $-5.29 | 44.93% |
AU
|
|
| $12.88 | -452.88% |
BE
|
|
| $21.56 | -690.68% |
NL
|
Questions about Odyssey Therapeutics, Inc.'s earnings per share (EPS)
What is Odyssey Therapeutics, Inc.'s earnings per share (EPS)?
Odyssey Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-3.65, as of Sep 2026.
How does Odyssey Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Odyssey Therapeutics, Inc.'s earnings per share (EPS) ($-3.65) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.